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Amyotrophic lateral sclerosis (ALS) is incurable and devastating. A dearth of 
therapies has galvanized experimental focus onto the cellular and molecular 
mechanisms that both initiate and subsequently drive selective motor neuron 
(MN) degeneration. A traditional view regarding ALS pathogenesis posits that 
disease-specific injury to a subtype of neurons is mechanistically cell-
autonomous. This “neuron-centric” view has biased past research efforts. 
However, a wealth of accumulating evidence now strongly implicates non-
neuronal cells as being major determinants of ALS. Although animal models have 
proven invaluable in basic neuroscience research, a growing number of studies 
confirm fundamental interspecies differences between popular model organisms 
and the human condition. This may in part explain the failure of therapeutic 
translation from rodent pre-clinical models. It follows that integration of a 
human experimental platform utilizing patient-specific induced pluripotent stem 
cells (hiPSCs) may be necessary to capture the complexity of human 
neurodegeneration with more fidelity. Integration of enriched human neuronal 
and glial experimental platforms into the existing repertoire of preclinical 
models might prove transformational for clinical trial outcomes in 
neurodegeneration. Such reductionist and integrated cross-modal approaches 
allow systematic elucidation of cell-autonomous and non-cell-autonomous 












Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and universally fatal 
condition, which leads to selective motor neuron (MN) degeneration [1]. ALS 
cases are predominantly sporadic (sALS) but approximately 10% are familial 
(fALS), the two being indistinguishable on clinical examination. Historically the 
first mutations linked to fALS were identified in the superoxide dismutase 1 
(SOD1) gene in 1993 [2], followed by an almost decade-long hiatus before a 
second phase of productive genetic discovery. Indeed, more than 20 different 
genes have now been linked to ALS, including relatively common mutations in 
chromosome 9 open reading frame 72 (C9ORF72) [3] and rarer mutations in TAR 
DNA Binding Protein (TARDBP) [4], Fused in Sarcoma/Translocated in Sarcoma 
(FUS) [5] and Valosin Containing Protein (VCP) [6], among several others. Until 
recently, studies examining the interplay between human neurons and glia in 
neurodegeneration have been hampered by relative inaccessibility to these 
cellular populations. The advent of hiPSCs through reprogramming technology, 
together with directed differentiation techniques, have greatly increased access, 
allowing researchers to obtain - a la carte – enriched populations of specific 
neuronal and glial cell types [7-9].  In order to harness the full potential of hiPSC 
models, an understanding of developmental principles underpinning the 
generation of neuronal and glial diversity is a prerequisite. Studies using this 
platform for disease modeling have largely focused on cell-autonomous 
mechanisms of neuronal degeneration, leaving the role of glia in this context 
comparatively understudied. 
Cellular interplay in the central nervous system (CNS) is spatio-temporally 
regulated in both development and disease. The major cellular contributors 
include a diverse range of region-specific neuronal subtypes in addition to both 
macro- and microglia (MG). Neurons and macroglia, astrocytes (ACs) and 
oligodendrocytes, are developmentally ectodermal in origin, while microglia 
arise from the mesoderm (yolk-sac). CNS cells exhibit both homotypic and 
heterotypic interactions, and show profound region-specific functional 
heterogeneity. Glia and neurons in the CNS interact with one another through 
direct contact (e.g. gap junctions or receptor-mediated), secreted factors (e.g. 
molecules or exosomes) or a combination of these, which are crucial to establish 
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and refine functional structures, including the tripartite synapse. Given such 
intricate connectivity, it seems eminently reasonable – if not likely - that glial 
cells would play key roles in the majority of neurological diseases. Indeed, cell-
autonomous and non-cell-autonomous glial mechanisms of disease are now 
increasingly being implicated as playing diverse and pivotal roles in human 
ageing and neurodegeneration [10]. 
Glia as pertetrators of ALS 
A ‘neuron-centric’ theoretical construct of ALS has been increasingly challenged 
over the last decade or two. The mechanisms by which glia can exert deleterious 
effects on neighboring neurons include i) through failure of support or 
homeostatic function, ii) toxic gain of function and release of toxic substances or 
iii) a combination of these mechanisms. Such effects can be contact-dependent 
and/or operate through a soluble factor (see Figure 1). Temporal aspects are 
also important to consider in this context; i.e. acute vs chronic activation of glial 
cells may well determine how effective their responses are in ALS and it is 
possible that chronic activation states eventually become maladaptive and 
adversely affect MNs. Assays to investigate cell-cell interactions can be 
experimentally operationalized through a variety of approaches, including i) co-
seeding different cell types, ii) “sandwich” cultures where two established 
monolayers are brought into close proximity, iii) transwell-based co-culture, iv) 
microfluidic devices and v) conditioned medium transfer. These approaches with 
their respective strengths and weaknesses have been recently reviewed 
elsewhere [11]. The choice of paradigm depends on whether the experiment 
aims to discriminate contact-dependent from contact-independent mechanisms 
of non-cell-autonomous injury. An important consideration here is the existence 
of cell-autonomous glial pathology, which remains relatively understudied in 
ALS and may indeed contribute to the failure of supportive capacity. Illuminating 
non-neuronal mechanisms of disease raises the important prospect of designing 
innovative therapeutic approaches that target glial cells. Further relevant and 
open questions in the field are presented in Box 1. We now discuss 2 exemplar 




Lessons from rodent models of ALS 
Microglia-motor neuron dialogue: The role of MG as a non-cell autonomous 
driver in MN degeneration has been studied in different experimental platforms, 
and a number of mechanisms proposed (Figure 1). Important mouse-chimera 
studies using lineage-specific expression of mutant SOD-1 first demonstrated the 
role of MNs in disease onset and early progression, while implicating MG as key 
drivers of late-phase disease progression [12]. Moreover, a subsequent study 
found that significant alterations in microglial populations are present in SOD-1 
models at pre-symptomatic stages, with a decrease in microglia before onset and 
the emergence of two distinct populations after symptom manifestation [13]. Of 
the several specific MG mechanisms that have been proposed, one study found 
significantly increased levels of the oncoprotein c-RET in activated microglia in 
SOD1G93A mice. The increase was cell-type specific (MG>MN), age-dependent, 
and proposed to non-cell-autonomously impair GDNF signaling in MNs [14]. 
More recent experiments have shown that expression of mutant SOD-1 
significantly increases MG secretion of neurotoxic cytokines [15] and that 
perturbing pro-inflammatory MG activation through deletion of NF-κB – a 
master regulator of inflammation - rescues MNs from MG-mediated death in 
models of ALS [16]. Indeed a micro-RNA (miR-125b) has been found to play a 
salient role in microglial activation through direct repression of ubiquitin-editing 
enzyme A20, a potent suppressor of the NF-κB pathway [17]. Further evidence 
implicating MG in the most common genetic form of ALS comes from mice 
lacking the C9orf72 ortholog in all tissues. Among other immune-related 
phenotypes, perturbed immune responses in microglia were uncovered [18]. 
Following earlier confirmation of TDP-43 in the cerebrospinal fluid of patients 
with ALS [19], a recent study also demonstrated that extracellular TDP-43 
aggregates can trigger activation of the NF-kB pathway in MG, invoking secretion 
of IL-1b and IL-18 [20]. Interestingly, a MG-specific inducible conditional TDP-43 
knockout mouse line resulted in significant synaptic loss, while enhancing 
amyloid clearance [21].  The importance of MG in ALS pathogenesis is further 
reinforced by the finding of an early innate immune response in the motor cortex 
of ALS SOD1G93A mice [22]. 
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Astrocyte-motor neuron dialogue: Several studies have implicated ACs in the 
pathobiology of ALS through a number of mechanisms, including both active and 
secondary toxicity (Figure 2).  An early study addressing this issue reported that 
restricted expression of SOD1G86R in ACs causes astrocytosis but not MN 
degeneration [23].  However, ex-vivo SOD1G93A ACs have subsequently been used 
in physical co-culture and AC conditioned medium (ACM) experiments, 
confirming that they are toxic to both primary and mouse embryonic stem cell 
(mESC)-derived MNs [24, 25]. Nagai and coworkers demonstrated that both 
toxicity and vulnerability are cell-type specific as only mutant ACs (not 
fibroblasts or other cell types) produced non-cell-autonomous toxicity. 
Additionally this effect was specifically directed towards MNs, while other 
neuronal subtypes including spinal GABAergic, dorsal root ganglion or mESC-
derived interneurons, were not affected. These aforementioned studies have 
established that toxic effects are mediated through a soluble factor and a BAX-
dependent mechanism [24, 25]. Di Giorgio and coworkers then confirmed that 
the same SOD1 non-cell-autonomous toxicity was evident when performing co-
cultures with hESC-derived MNs [26]. 
A number of alternative possible mechanisms exist through which AC-mediated 
MN injury can occur, either through loss of supportive function or active toxicity. 
These include perturbations in: expression of AC receptors / transporters, 
release or metabolism of AC transmitters, synthesis and release of chemokines, 
cytokines, and free radical generation or coupling of gap junctions (Figure 1B). 
SOD1G93A astrocytes were found to be a key driver of disease progression in an 
ALS model [27]. Indeed, transplanted ACs expressing mutant SOD1 induce MN 
degeneration in wild-type rats [28]. Particularly in SOD1 models, active AC 
toxicity to MNs has been observed, mediated by production of reactive oxygen 
species, which has been shown to induce MN hyper-excitability [29, 30] and MN 
degeneration through mitochondrial dysfunction in ACs [31]. Another proposed 
mechanism for direct non-cell autonomous toxicity to MNs is AC-mediated 
perturbation of MN autophagy, exacerbating underlying cell-autonomous 
toxicity by decreasing MN ability to handle accumulating misfolded proteins [32, 
33]. 
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Although relatively understudied, a number of non-cell autonomous mechanisms 
derive from loss of supportive capacity rather than active toxicity. For example, 
SOD1G93A fALS ACs induce MN death at least in part through reducing metabolic 
support (lactate release) and activating pro-nerve growth factor-p75 receptor 
signaling pathway at the expense of mature nerve growth factor production [34]. 
Converging lines of evidence suggest that regulation of the AC glutamate 
transporter EAAT2 in ALS non-cell-autonomously determines MN survival. The 
intuitive mechanism here is excitotoxicity through failure of AC glutamate 
clearance [35], although one study has suggested that sumoylated carboxy-
terminal fragments of EAAT2 accumulate in the AC nucleus and cause impaired 
axonal growth in co-cultured MNs independently of excitotoxicity [36]. Another 
example of loss of AC support is the disrupted GluR2-regulating capacity of 
mutant SOD1 ACs, which renders MNs vulnerable to excitotoxicty [37]. A BCL-2 
family protein called Bid is elevated in SOD1G93A ACs and acts as a key regulator 
for activating NF-κB [38]. In contrast to MG, selective NF-κB inhibition in ACs is 
not sufficient to rescue MN death [16]. NLRP3 ‘inflammasome’ complexes are 
crucial for the processing and release of IL1b and IL18, and are predominantly 
expressed in ACs [39]. To add further complexity, a regionally determined 
functional heterogeneity of ACs [40] might underlie region-specific responses to 
the same mode of injury. Furthermore, different phases of the same disease may 
invoke diverse responses in ACs.  
Beyond the glial-neuronal dialogue: Lineage specific translational profiling in a 
SOD1G37R model has revealed sequential changes first in MNs (ER stress, synapse 
and metabolic changes) followed by ACs (abnormal inflammatory responses and 
metabolism) and then oligodendrocytes (membrane and lipid signaling defects) 
reinforcing the concept of cell type-specific contributions to different phases of 
disease [41]. Indeed stereotyped intercellular interactions are likely also 
perturbed in a disease stage-specific manner (Figure 3).  In vivo, diminished AC 
SOD1G93A expression, in addition to slowing disease progression, also delayed 
MG activation [27]. Conversely, transplantation of SOD1G93A ACs into wild-type 
rats caused MN degeneration, at least in part, through MG activation [28]. 
Indeed, AC activation by ALS MNs stimulates secretion of lipocalin (lcn2) in rats, 
which in turn orchestrates and amplifies various downstream effects through 
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actions on quiescent ACs, MG and MNs [42]. Subsequent studies have suggested 
that AC-derived TGF-β1 accelerates disease progression in vivo by interfering 
with the neuroprotective functions of MG and T cells [43]. MG-AC signaling can 
also lead to the acquisition of toxic functions in ACs. Specifically, a recent study 
demonstrated that by secreting Il-1α, TNF and C1q, activated microglia induce a 
toxic AC phenotype, which impairs their ability to promote neuronal survival, 
synaptogenesis and phagocytosis [44]. An intriguing set of experiments has also 
raised the possibility of cell fate transition from MG into AC-like cells, which 
coincides with disease onset in a model of inherited ALS [45]. Clearly there will 
exist myriad cellular mechanisms of disease beyond MNs, MG and ACs. Indeed 
there is an early but evolving literature in ALS implicating several other neuronal 
subtypes (e.g. interneurons [46, 47]), glia (e.g. oligodendrocytes [48, 49]) and 
immune cells including CD4+ regulatory T cells, cytotoxic CD8+ T cells and 
natural killer cells [50-52].  
Limitations of animal ALS models: From the selected examples above, it is clear 
that animal models are indispensible and have provided invaluable insight into 
issues of cellular autonomy in ALS. It is noteworthy, however, that the vast 
majority of studies have been performed in overexpression SOD1 models, which 
do not convey mutant proteins at pathophysiological levels. Crucially, SOD1 
mutations do not exhibit the major pathological hallmark of TDP-43 
proteinopathy as observed in >97% of human ALS cases [53]. This pathological 
difference reinforces the importance of validating findings from SOD1 models in 
other experimental platforms that recapitulate this hallmark feature. More 
broadly, there has been an overwhelming failure of translation from animal pre-
clinical models of neurodegeneration to impactful clinical therapies, possibly 
reflecting underlying interspecies differences. Many clear evolutionary 
differences exist between mice and man, including at gross neuroanatomical, 
circuit, cellular and molecular levels [54]. To capture the complexity of the 
human clinical disease state with precision, it seems imperative to complement 
existing animal-based approaches with human experimental pre-clinical models, 
such as hiPSCs but also with postmortem tissue. We will now focus on how 
human platforms can help to directly elucidate issues of cellular autonomy in 
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neurodegeneration (see Box 2), while the wider relevance of hiPSCs in 
regenerative neurology has recently been reviewed elsewhere [55]. 
Delineating cellular autonomy in human ALS 
Human post-mortem tissue: laser capture microdissection of human post-mortem 
tissue seems an attractive approach to deconvoluting cell type-specific 
contributions in neurological disease. However, this method introduces bias 
towards the cellular soma and away from the axon and dendrites (which are less 
efficiently captured). Likewise, the neuropil often ‘contaminates’ attempts to 
isolate glial cells using this approach. A large selection of post-mortem samples 
across different age groups raises the prospect of uncovering age-dependent 
changes in the human brain, which represents a crucial risk factor for 
neurodegeneration. Indeed bioinformatic approaches have recently been 
successfully utilized to deconvolute cell-type specific transcriptional signatures 
upon ageing from microarray-based studies of heterogeneous postmortem tissue 
[56]. It is also possible to ‘immunopan’ specific cell types from postmortem 
tissue, as was recently performed across a diverse age range to characterize 
temporal changes in the AC transcriptome [57]. A similar study conducted 
transcriptome-wide analyses on purified MG from mouse and human tissue and 
reported a divergence in age-related expression patterns, further reinforcing the 
importance of validating key experimental findings with human samples [58]. 
Human post mortem tissue additionally permits ex-vivo culture of certain cell 
types, which has proved a valuable resource for studies of human AC-mediated 
non-cell-autonomous injury [59, 60] (discussed further below). An important 
consideration of human postmortem tissue is that it represents a late stage of 
disease, and cannot therefore effectively inform on early pathogenic events. 
Indeed, even in cases obtained early in their disease course, it is important to 
recognize that at a molecular and cellular level, the disease processes are 
underway years before clinical symptoms appear and even these cases will 
therefore not allow elucidation of early molecular pathogenic events. The use of 
post-mortem tissue is further complicated by varying post-mortem intervals of 
delay, which can introduce significant variability between studies, but 
nevertheless represents a crucial approach in understanding cellular autonomy 
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in neurodegeneration (particularly when integrated with the other experimental 
model systems discussed in this review). 
HiPSCs: the state-of-the-art. The iPSC platform offers the ability to direct 
differentiation to any human lineage in an ontogeny-recapitulating manner. A 
fundamental prerequisite to establishing iPSC models is therefore a robust 
understanding of the developmental programmes of morphogenetic cues 
required to direct differentiation to regionally specified neuronal and glial 
subtypes; as recently reviewed elsewhere [10, 61-64]. This presents the 
experimental opportunity to resolve molecular mechanisms that underlie 
distinct stages of lineage restriction to different neuronal and glial subtypes by 
faithfully recapitulating human neurodevelopment [65]. This is a crucial 
advantage as a recognized phase of compensated dysfunction occurs prior to 
clinical manifestation of neurodegenerative disease. Furthermore, patient-
specific iPSCs convey mutations at pathophysiological levels (or the underlying 
genetic complement in sporadic cases). These attributes together make hiPSCs a 
powerful experimental tool capable of deconvoluting the complexity of 
heterologous cell-cell interactions in health and disease.   
Where underlying developmental programmes are well understood and defined 
neuronal subtypes can be specified, hiPSC biology has led to a step change in the 
discovery of cellular and molecular phenotypes or therapeutic potential [66-74]. 
Elucidation of cell-autonomous mechanisms of disease is eminently achievable 
through enriched monoculture of a particular cell type. Indeed, generating 
regionally distinct populations of neurons (e.g. spinal motor neurons and cortical 
neurons) can help to discriminate neuronal subtype vulnerability [75] or identify 
shared mechanisms in multi-regional disorders (e.g. the spectrum of ALS and 
frontotemporal lobar dementia [76]). Researchers can build on these early 
phenotyping studies by probing neuronal or glial monoculture responses to 
physiological stimuli [77, 78] or by incrementally adding cellular complexity 
through co-culture paradigms [79]. These approaches permit deeper 
understanding of non-cell-autonomous mechanisms of disease as they combine 
some of the complexity of in vivo circuitry with the ability to ‘control’ the in vitro 
system. Human iPSC-based models also allow fully human co-culture paradigms, 
which addresses concern over species-specific aspects of intercellular 
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communication. Techniques such as high-content imaging (HCi) have provided 
crucial insights into cellular vulnerability by increased assay sensitivity when 
compared with traditional cross-sectional imaging methods [79-82]. However, 
one of the main rate-limiting factors has been elucidating the developmental 
programme of morphogenetic cues to direct differentiation to regionalized 
subtypes of neurons in high enough enrichment. For example, studies 
systematically examining upper MNs (i.e. cortical layer V) in ALS using hiPSCs 
are lacking. This is largely due to the difficulty in specifying distinct cortical 
layers reproducibly and in an enriched manner. The lack of reliable cell surface 
markers for cortical MNs further compounds this problem.  
AC-mediated non-cell-autonomous mechanisms of disease that were first 
described in ALS animal models over the last decade or so, have been broadly 
validated and extended in a variety of human models (hiPSCs and ex-vivo 
cultures derived from port-mortem cases); representative studies are 
summarized in table 1. Evidence thus far points clearly to release of toxic 
substances by ACs, although failure of supportive mechanisms remains relatively 
understudied in the human context. Importantly, the hiPSC platform also allows 
dissection of early AC cell autonomous effects in ALS [78-80], which adds an 
additional layer of complexity to the intricate cellular interplay. AC survival 
defects are often difficult to capture through traditional cross-sectional analysis 
due to the fact that astrocytes retain proliferative capacity, thus reinforcing the 
utility of a HCi approach [82]. Another crucial aspect to consider is the level of 
maturation and functional activation achievable in glial cultures derived from 
patient-specific iPSCs. Although iPSC-AC populations have been functionally 
characterized in vitro [80, 83, 84], a comprehensive functional comparison with 
in vivo ACs has only been attempted recently in one elegant study [85]. Few 
studies have attempted to define basal human iPSC-derived AC reactivity state, 
and how this might be manipulated (i.e. to induce quiescence or reactivity) in 
order to examine their effects in different disease paradigms [78, 86, 87]. 
Increasing recognition of region-specific functional heterogeneity of ACs [40, 88, 
89] also argues for studies focusing on their regional specification from hiPSCs; 
indeed spinal and cortical AC specification has already been accomplished [84]. 
Directed differentiation of MG from hiPSCs has also been achieved [90], and this 
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will be an important tool to resolve cell-autonomous and non-cell-autonomous 
effects of human MG in ALS, following on from earlier rodent studies 
summarized above.  
It remains unresolved how early molecular disturbances begin and the 
hypothesis that adult-onset neurogenetic disorders may be manifest at 
molecular and cellular levels during neurodevelopment is supported by the 
numerous hiPSC studies demonstrating clear phenotypes in what is essentially a 
developmental system (reviewed in [10, 55]). Indeed, existing evidence suggests 
that hiPSC derivatives upon terminal differentiation resemble a fetal 
maturational state [67, 91, 92]. One strategy to ‘preserve’ the age of the donor 
cell is to bypass induction of pluripotency and directly ‘transdifferentiate’ 
fibroblasts into a target neuronal or glial population [93], although this approach 
has the disadvantage of limited expansion of the target population. Recent 
studies have also pharmacologically induced ageing using the telomerase 
inhibitor 2-[(E)-3-naphtha- len-2-yl-but-2-enoylamino]-benzoic acid (BIBR1532) 
[94] or expression of Progerin, a truncated form of lamin A that is associated 
with premature aging [67]. In other cases researchers have successfully cultured 
cells over a protracted period of time to uncover age-related phenotypes [95]. 
Cellular ageing in vitro is likely to result from a complex interplay of different 
factors and gene expression programs [92, 93]. Future protocols to induce 
cellular ageing in vitro are likely to use a combinatorial approach, including co-
culture with non-neuronal cell types. Clearly the in vivo environment may readily 
compensate such initiating molecular perturbations but their identification is 
crucial in guiding mechanistically targeted therapies. Furthermore, delineation 
of culprit cell types and how they conspire in neurodegeneration will clearly be 
of paramount importance in considering therapeutic strategy. Given the 
developmental nature of the hiPSC paradigm, the stability of cellular identity is 
also worthy of consideration, particularly in the setting of co-cultures where 
either cellular component may encounter a range of unfamiliar extrinsic cues. 
Another noteworthy limitation of hiPSC studies so far is the lack of ordered 
architecture in cell-cell interactions. While neurons and glia in vivo interact 
within the context of organized circuitry (e.g. upper MN to lower MN to muscle), 
most hiPSC in vitro models lack the ability to organize into a cellular 
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configuration that resembles the original circuit architecture in vivo due to facile 
culture substrates used. This can potentially be overcome by exploiting the 
interface between stem cell technology and bioengineering approaches to 
impose basic characteristics like directionality to approximate physiologically 
functional circuits. Introducing 3D culture systems to hiPSC modeling is also 
noteworthy here. Several “organ-on-chip” systems have been developed 
specifically for recapitulating aspects of neurodevelopment in vitro, including: (i) 
bioengineering solutions to physically guide axonal extension while segregating 
different cell types in different chambers to evaluate drug-treatments and 
cellular interactions [96-98], in some cases permitting direct recording of 
neuronal activity [99]; (ii) co-culture of different neuronal populations to create 
complex networks but in an organized fashion, resembling in vivo neuronal 
circuitry [100]; (iii) generating 3D structures form hiPSC-derived neural 
precursors, either using artificial scaffolds [101-103] or creating brain 
‘organoids’ [104-106]. Combining these approaches allows for a more complex 
culture system in vitro, permitting multi-lineage disease modeling. Recent 
examples relevant to ALS include bioengineered neuromuscular junctions in 
vitro [107, 108]. These approaches extend disease modeling beyond enriched 
monoculture of an individual cell type to recapitulation of neuronal circuits, 
which will in turn evolve to multilineage co-cultures permitting insight into the 




To systematically gain insight into the cellular interplay underlying 
neurodegeneration, it is crucial to first elucidate cell-autonomous phenotypes in 
monoculture. This then serves as a useful reference for co-culture experiments. 
Additionally, discerning whether specific mechanisms of non-cell-autonomous 
injury require cell-cell contact or are diffusible in nature will help to inform 
optimal approaches to therapy development. To complement this human in-vitro 
modeling approach, in-vivo studies can provide crucial insight into the sequence 
of cellular involvement in a specific disease. Likewise, human postmortem tissue 
can then provide useful information about later stages of a disease process by 
correlating neuropathology with the clinical history [109-113]. It is important to 
 14 
recognize that each disease model alone does not capture the full complexity of 
human pathophysiology, and so integrating human and animal experimental 
models with human post-mortem tissue work is a key step to driving high-
confidence cross-modal discovery science. The overarching purpose of 
uncovering cell-autonomous and non-cell-autonomous mechanisms of disease is 
to identify which processes within (and between) neurons and glia represent 
crucial ‘tipping’ points from a state of compensated dysfunction to irreversible 
decompensation and neurodegeneration. This approach will help to prioritise 
therapeutic efforts around these specific salient events, which will likely have 















Figure 1. Microglial non-cell autonomous toxicity. A number of non-cell 
autonomous mechanisms of toxicity have been observed in MG-MN interactions, 
placing MG as important players in driving pathology. Active toxicity 
mechanisms (A) include increased levels of c-RET, secretion of pro-inflammatory 
factors and direct toxicity via secretion of yet unidentified mediators. MG 
dysfunction has also been observed as a consequence of exposure to stress 









Figure 2. Astrocyte non-cell autonomous toxicity. AC non-cell autonomous 
toxicity to MNs has been demonstrated in a wide range of models and definitely 
has a central role in disease progression. Several direct gain of toxic function 
mechanisms have been described (A) including: production of ROS, secretion of 
mutant proteins (e.g. SOD1) in the extracellular space, or other secondary 
dysfunction. ACs can also inhibit key coping mechanisms that exacerbate 
underlying MN cell-autonomous toxicity, for example autophagy. A range of 
putative loss of functional mechanisms have been reported (C), including 
reduced EAAT2 expression or failure to regulate GluR2 expression in MNs, both 
leading to excitotoxicity. Similarly depletion of functional AC populations due to 
cell autonomous glial toxicity is noteworthy here. 
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Figure 3. A cycle of cellular autonomy in ALS pathobiology. The complex 
interplay between MNs, AC and MG changes during different phases of disease 
and the non-cell autonomous effects of glial cells can be both causes and 
consequences of cell-autonomous toxicity in MNs. For example, during the early 
phases of disease, cell-autonomous toxicity and non-cell autonomous active 
toxicity from ACs causes damage to the MN populations and release of stress 
response factors and mutant proteins; this in turn acts as a trigger for the 
activation of a neuro-inflammatory response in MG cells, which then become 
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